Overview
- Temple began taking pre‑orders on November 1 for a made‑to‑order forehead sensor priced at ₹85,000 with shipments expected in early 2027.
- Deepinder Goyal publicly defended the product on X, saying Temple has spent about $30 million to develop the device, $20 million of it his own money, and pointed to a 14‑day no‑questions‑asked return as proof of confidence.
- Several doctors have publicly criticised Temple’s headline claims, arguing the device’s optical photoplethysmography over the superficial temporal artery measures scalp and facial blood flow and cannot, by itself, be assumed to reflect cerebral (intracranial) blood circulation.
- Independent validation is lacking: the studies Temple has cited are company‑funded preprints rather than peer‑reviewed, and physicians have demanded transparent methods, peer review and replication before accepting the device’s proprietary 'BrainFlow' and 'Entropy' metrics.
- The dispute highlights wider issues for consumers and regulators about where wellness trackers end and medical diagnostics begin; Temple says broader validation and independent studies will follow once units are in users’ hands, echoing past wearables that released data after shipping.